Press release
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Analysis, Trends, Growth, Research And Forecast 2033
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.88 billion In 2028 At A CAGR Of 7.4% :
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.
The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.
Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Major Segments
The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented -
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
Key Driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.
Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=13031&type=smp
Prominent Trend - Leading Companies In The Cinv Market Pioneering Transdermal Delivery System (TDS) Innovations
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Players
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
View The Full Report Here - https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
Largest And Fastest Growing Region In The Market
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2023. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report Structure
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Analysis, Trends, Growth, Research And Forecast 2033 here
News-ID: 3557585 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for CINV
Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vom …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market encompassing chemotherapy-induced nausea and vomiting treatments has witnessed substantial expansion, projected to increase its valuation from $2.92 billion in 2024 to $3.13 billion in 2025, reflecting a compound annual growth…
CINV Treatment Market to Reach USD 3.9 Billion by 2034
Pune, India, November 11, 2025 - The global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market is projected to grow from USD 2.6 billion in 2024 to USD 3.9 billion by 2034, registering a CAGR of 4.1 %, according to Exactitude Consultancy. Rising cancer incidence, increasing chemotherapy adoption, and development of next-generation serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists are driving global market expansion.
Download Full PDF Sample Copy of Market Report…
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
